139 related articles for article (PubMed ID: 36270249)
1. Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas.
Shi Z; Ge X; Li M; Yin J; Wang X; Zhang J; Chen D; Li X; Wang X; Ji J; You Y; Qian X
Mol Cell; 2022 Oct; 82(20):3919-3931.e7. PubMed ID: 36270249
[TBL] [Abstract][Full Text] [Related]
2. Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation.
Akıncılar SC; Khattar E; Boon PL; Unal B; Fullwood MJ; Tergaonkar V
Cancer Discov; 2016 Nov; 6(11):1276-1291. PubMed ID: 27650951
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
[No Abstract] [Full Text] [Related]
4. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations in telomere biology.
Heidenreich B; Kumar R
Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
[TBL] [Abstract][Full Text] [Related]
6. GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer.
McKinney AM; Mathur R; Stevers NO; Molinaro AM; Chang SM; Phillips JJ; Costello JF
Cell Rep; 2022 Sep; 40(12):111344. PubMed ID: 36130485
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.
Yuan X; Dai M; Xu D
Cancer Lett; 2020 Nov; 493():1-9. PubMed ID: 32768523
[TBL] [Abstract][Full Text] [Related]
8. TERT Promoter Mutations Enhance Telomerase Activation by Long-Range Chromatin Interactions.
Min J; Shay JW
Cancer Discov; 2016 Nov; 6(11):1212-1214. PubMed ID: 27807101
[TBL] [Abstract][Full Text] [Related]
9. GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
Yuan X; Mu N; Wang N; Strååt K; Sofiadis A; Guo Y; Stenman A; Li K; Cheng G; Zhang L; Kong F; Ekblad L; Wennerberg J; Nilsson IL; Juhlin CC; Larsson C; Xu D
Oncogene; 2019 Feb; 38(7):965-979. PubMed ID: 30181547
[TBL] [Abstract][Full Text] [Related]
10. Cancer-specific loss of
Amen AM; Fellmann C; Soczek KM; Ren SM; Lew RJ; Knott GJ; Park JE; McKinney AM; Mancini A; Doudna JA; Costello JF
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33758097
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
12. Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.
Mancini A; Xavier-Magalhães A; Woods WS; Nguyen KT; Amen AM; Hayes JL; Fellmann C; Gapinske M; McKinney AM; Hong C; Jones LE; Walsh KM; Bell RJA; Doudna JA; Costa BM; Song JS; Perez-Pinera P; Costello JF
Cancer Cell; 2018 Sep; 34(3):513-528.e8. PubMed ID: 30205050
[TBL] [Abstract][Full Text] [Related]
13. GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer.
Guo Y; Yuan X; Li K; Dai M; Zhang L; Wu Y; Sun C; Chen Y; Cheng G; Liu C; Strååt K; Kong F; Zhao S; Bjorkhölm M; Xu D
Cell Death Differ; 2020 Jun; 27(6):1862-1877. PubMed ID: 31802036
[TBL] [Abstract][Full Text] [Related]
14. Programmable base editing of mutated TERT promoter inhibits brain tumour growth.
Li X; Qian X; Wang B; Xia Y; Zheng Y; Du L; Xu D; Xing D; DePinho RA; Lu Z
Nat Cell Biol; 2020 Mar; 22(3):282-288. PubMed ID: 32066906
[TBL] [Abstract][Full Text] [Related]
15. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.
Stern JL; Theodorescu D; Vogelstein B; Papadopoulos N; Cech TR
Genes Dev; 2015 Nov; 29(21):2219-24. PubMed ID: 26515115
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression.
Beck S; Jin X; Sohn YW; Kim JK; Kim SH; Yin J; Pian X; Kim SC; Nam DH; Choi YJ; Kim H
Mol Cells; 2011 Jan; 31(1):9-15. PubMed ID: 21193962
[TBL] [Abstract][Full Text] [Related]
17. Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
Aquilanti E; Kageler L; Watson J; Baird DM; Jones RE; Hodges M; Szegletes ZM; Doench JG; Strathdee CA; Figueroa JRMF; Ligon KL; Beck M; Wen PY; Meyerson M
Neuro Oncol; 2023 Jul; 25(7):1275-1285. PubMed ID: 36694348
[TBL] [Abstract][Full Text] [Related]
18. Recurrent epimutations activate gene body promoters in primary glioblastoma.
Nagarajan RP; Zhang B; Bell RJ; Johnson BE; Olshen AB; Sundaram V; Li D; Graham AE; Diaz A; Fouse SD; Smirnov I; Song J; Paris PL; Wang T; Costello JF
Genome Res; 2014 May; 24(5):761-74. PubMed ID: 24709822
[TBL] [Abstract][Full Text] [Related]
19. Understanding TERT Promoter Mutations: A Common Path to Immortality.
Bell RJ; Rube HT; Xavier-Magalhães A; Costa BM; Mancini A; Song JS; Costello JF
Mol Cancer Res; 2016 Apr; 14(4):315-23. PubMed ID: 26941407
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter alterations could provide a solution for Peto's paradox in rodents.
Vedelek B; Maddali AK; Davenova N; Vedelek V; Boros IM
Sci Rep; 2020 Nov; 10(1):20815. PubMed ID: 33257697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
